SPOTLIGHT: Cancer cost hike tempered by generics


The average annual drug cost per cancer patient has reached new highs--$13,113 as of January 1, compared with $6,490 in 2001--but a new report shows that generics are being used more often, helping to slow the rate of that cost increase. Report

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.